Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst

After hitting a home run with trial results for Dupixent in chronic obstructive pulmonary disease (COPD), Sanofi and Regeneron are circling the bases, considering an exciting future with another lucrative indication.

What would it mean for the top lines of the companies if Dupixent becomes the first significant treatment advance for COPD in more than a decade and the first biologic approved for the elusive condition?